UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

The New England journal of medicine, 2021-08, Vol.385 (6), p.493-502

2021

Volltextzugriff (PDF)

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

The lancet oncology, 2018-04, Vol.19 (4), p.497-509

2018

Volltextzugriff (PDF)

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

Journal of clinical oncology, 2015-01, Vol.33 (2), p.172-179

2015

Volltextzugriff (PDF)

Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial

JAMA surgery, 2020-03, Vol.155 (3), p.e195410

2020

Volltextzugriff (PDF)

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies

Gynecologic oncology, 2018-03, Vol.148 (3), p.507-514

2018

Volltextzugriff (PDF)

CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema

The New England journal of medicine, 2024-02, Vol.390 (5), p.432-441

2024

Volltextzugriff (PDF)

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors

OncoTargets and therapy, 2017-01, Vol.10, p.4239-4250

2017

Volltextzugriff (PDF)

Monobenzyl Ether of Hydroquinone and 4-Tertiary Butyl Phenol Activate Markedly Different Physiological Responses in Melanocytes: Relevance to Skin Depigmentation

Journal of investigative dermatology, 2010-01, Vol.130 (1), p.211-220

2010

Volltextzugriff (PDF)

Reply to M. Bouattour et al

Journal of clinical oncology, 2015-08, Vol.33 (22), p.2486-2486

2015

Volltextzugriff (PDF)

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer

Journal of clinical oncology, 2015-02, Vol.33 (5), p.433-441

2015

Volltextzugriff (PDF)

Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib

Lung cancer (Amsterdam, Netherlands), 2015-11, Vol.90 (2), p.296-301

2015

Volltextzugriff (PDF)

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

Investigational new drugs, 2015-08, Vol.33 (4), p.870-880

2015

Volltextzugriff (PDF)

The prognostic significance of margin width for extremity and trunk sarcoma

Journal of surgical oncology, 2004-02, Vol.85 (2), p.68-76

2004

Volltextzugriff (PDF)

A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)

Cancer chemotherapy and pharmacology, 2014-07, Vol.74 (1), p.37-43

2014

Volltextzugriff (PDF)

Pancreaticobiliary reflux and gallbladder cancer

Journal of surgical oncology, 2007-11, Vol.96 (6), p.455-456

McKee, Mark D.

2007

Volltextzugriff (PDF)

Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer

Clinical colorectal cancer, 2014-09, Vol.13 (3), p.156-163.e2

2014

Volltextzugriff (PDF)

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors

Cancer chemotherapy and pharmacology, 2012-06, Vol.69 (6), p.1477-1486

2012

Volltextzugriff (PDF)

T cell immunotherapy

Frontiers in bioscience, 2007-01, Vol.12 (1), p.919

2007

Volltextzugriff (PDF)

Melanoma-Associated Antigen Expression in Lymphangioleiomyomatosis Renders Tumor Cells Susceptible to Cytotoxic T Cells

The American journal of pathology, 2009-12, Vol.175 (6), p.2463-2472

2009

Volltextzugriff (PDF)

T cell avidity and tumor recognition: implications and therapeutic strategies

Journal of translational medicine, 2005-09, Vol.3 (1), p.35-35, Article 35

2005

Volltextzugriff (PDF)

Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment

Cancer research (Chicago, Ill.), 2009-04, Vol.69 (7), p.3077-3085

2009

Volltextzugriff (PDF)

The Wave Front Set Correspondence for Dual Pairs with One Member Compact

Acta mathematica Sinica. English series, 2024-03, Vol.40 (3), p.823-869

2024

Volltextzugriff (PDF)

Targeted Therapy for Solid Tumors: Current Status

Surgical oncology clinics of North America, 2008-04, Vol.17 (2), p.279-301

2008

Volltextzugriff (PDF)

Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition

Hepatology (Baltimore, Md.), 2006-05, Vol.43 (5), p.973-981

2006

Volltextzugriff (PDF)

CD8-Independent Tumor Cell Recognition Is a Property of the T Cell Receptor and Not the T Cell

The Journal of immunology (1950), 2003-03, Vol.170 (5), p.2582-2589

2003

Volltextzugriff (PDF)

1 – 25 von 843

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(719)
Mit Volltextzugriff
(729)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies

CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors

Monobenzyl Ether of Hydroquinone and 4-Tertiary Butyl Phenol Activate Markedly Different Physiological Responses in Melanocytes: Relevance to Skin Depigmentation

Reply to M. Bouattour et al

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer

Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

The prognostic significance of margin width for extremity and trunk sarcoma

A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)

Pancreaticobiliary reflux and gallbladder cancer

Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors

T cell immunotherapy

Melanoma-Associated Antigen Expression in Lymphangioleiomyomatosis Renders Tumor Cells Susceptible to Cytotoxic T Cells

T cell avidity and tumor recognition: implications and therapeutic strategies

Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment

The Wave Front Set Correspondence for Dual Pairs with One Member Compact

Targeted Therapy for Solid Tumors: Current Status

Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition

CD8-Independent Tumor Cell Recognition Is a Property of the T Cell Receptor and Not the T Cell

Suchergebnisse filtern